Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

4 terminated/withdrawn out of 10 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

7(70.0%)

Phase 2

3(30.0%)

10Total

Phase 1(7)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT02540161Phase 2Completed

Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma

Role: lead

NCT01989052Phase 1Terminated

Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma

Role: lead

NCT01954030Phase 1Terminated

Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure

Role: lead

NCT00979173Phase 1Completed

Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma

Role: lead

NCT00953121Phase 2Completed

Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)

Role: lead

NCT01017653Phase 2Terminated

Panitumumab and Irinotecan for Malignant Gliomas

Role: lead

NCT00613223Phase 1Completed

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

Role: lead

NCT00613132Phase 1Completed

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

Role: lead

NCT00613054Phase 1Completed

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

Role: lead

NCT00734864Phase 1Withdrawn

Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

Role: lead

All 10 trials loaded